Lumida
/CHRS
⌘K
Coherus Oncology Inc

Coherus Oncology Inc

CHRS
$1.33USD-0.75%-0.01 today

MARKET CAP

205.5M

P/E (TTM)

0.8x

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

CHRS remains in a Stage 4 decline with a confirmed LH/LL regime and price below downward-sloping EMAs, supporting a medium-term bearish bias. The recent bounce into the 9/21EMA zone lacks follow-through, making immediate selling unfavorable. We defer execution, trimming into rallies at EMAs and prior resistance areas rather than chasing current extension.

  • Q2 2026 revenue $13.6M (+37% YoY; +15% QoQ) driven by Lactorsi.
  • Cash $105.3M after cutting R&D to $21.4M and SG&A to $21M.
  • Net loss narrowed to $33.3M (-$0.22/share) remains significant.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$326.6M$211.0M$257.2M$26.4M$42.2M
YoY %-31.4%-35.4%+21.9%-89.7%+59.8%
P / Sales3.7x3.1x1.1x6.0x3.9x
EV / Sales4.2x5.8x3.9x23.2x6.5x
Gross Profit, Adj.$269.0M$141.0M$98.3M$17.7M$28.4M
YoY %-38.6%-47.6%-30.3%-82.0%+60.6%
Margin %82.4%66.8%38.2%66.9%67.2%
EV / Gross Profit5.1x8.6x10.3x34.7x9.7x
EBITDA, Adj.$-260.4M$-253.2M$-199.4M$-194.4M$-177.2M
YoY %-263.6%+2.8%+21.2%+2.5%+8.8%
Margin %-79.7%-120.0%-77.5%-736.6%-420.2%
EV / EBITDA-5.3x-4.8x-5.1x-3.2x-1.6x
EBIT$-263.9M$-256.9M$-203.2M$-199.7M$-181.1M
YoY %-268.8%+2.6%+20.9%+1.7%+9.3%
Margin %-80.8%-121.7%-79.0%-756.6%-429.5%
EV / EBIT-5.2x-4.7x-5.0x-3.1x-1.5x
Net Income$-287.1M$-291.8M$-237.9M$28.5M$168.0M
YoY %-317.1%-1.6%+18.5%+112.0%+489.4%
Net Margin-87.9%-138.2%-92.5%108.0%398.4%
EPS (GAAP)-$3.81-$3.76-$2.53$0.25$1.43
YoY %-335.2%+1.3%+32.7%+109.9%+472.0%